June 29, 2017 07:10 AM EDTUpdated June 28, 02:22 PM
Financing

At­las Ven­ture vows to keep do­ing well by do­ing good with its new, $350M biotech fund

John Carroll

Editor & Founder

One of the most promi­nent biotech in­cu­ba­tors in the ven­ture busi­ness has launched a new $350 mil­lion fund to help fu­el a new wave of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

FDA ap­proves Mod­er­na’s next-gen Covid vac­cine, with lim­its on most healthy peo­ple

Sum­mit says bis­pe­cif­ic miss­es over­all sur­vival in close­ly-watched lung can­cer study

Sum­mit’s dis­ap­point­ing sur­vival read­out rais­es stakes for full da­ta

Gilead, Mer­ck re­veal 'prac­tice-chang­ing' da­ta for Trodelvy-Keytru­da com­bo in ag­gres­sive breast can­cer

An­oth­er Bris­tol My­ers ex­ec goes to Aca­dia; David South­well takes CEO job at ARCH-backed can­cer biotech

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times